- Home
- CRBP vs JLS Comparison
CRBP vs JLS Comparison
Compare CRBP & JLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- JLS
- Stock Information
- Founded
- CRBP 2009
- JLS 2009
- Country
- CRBP United States
- JLS United States
- Employees
- CRBP N/A
- JLS N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- JLS Investment Managers
- Sector
- CRBP Health Care
- JLS Finance
- Exchange
- CRBP Nasdaq
- JLS Nasdaq
- Market Cap
- CRBP 110.3M
- JLS 103.4M
- IPO Year
- CRBP N/A
- JLS N/A
- Fundamental
- Price
- CRBP $9.79
- JLS $18.76
- Analyst Decision
- CRBP Strong Buy
- JLS
- Analyst Count
- CRBP 10
- JLS 0
- Target Price
- CRBP $53.22
- JLS N/A
- AVG Volume (30 Days)
- CRBP 107.9K
- JLS 26.6K
- Earning Date
- CRBP 08-05-2025
- JLS 01-01-0001
- Dividend Yield
- CRBP N/A
- JLS 9.33%
- EPS Growth
- CRBP N/A
- JLS N/A
- EPS
- CRBP N/A
- JLS N/A
- Revenue
- CRBP N/A
- JLS N/A
- Revenue This Year
- CRBP N/A
- JLS N/A
- Revenue Next Year
- CRBP $270.04
- JLS N/A
- P/E Ratio
- CRBP N/A
- JLS N/A
- Revenue Growth
- CRBP N/A
- JLS N/A
- 52 Week Low
- CRBP $4.64
- JLS $15.48
- 52 Week High
- CRBP $61.89
- JLS $17.97
- Technical
- Relative Strength Index (RSI)
- CRBP 62.32
- JLS 45.50
- Support Level
- CRBP $8.88
- JLS $18.66
- Resistance Level
- CRBP $9.59
- JLS $19.00
- Average True Range (ATR)
- CRBP 0.59
- JLS 0.13
- MACD
- CRBP 0.03
- JLS -0.03
- Stochastic Oscillator
- CRBP 78.45
- JLS 28.56
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.